October 1, 2021 10:19 AM EDTUpdated 10:59 AM
Deals
Manufacturing

Emer­gent lands an­oth­er big mon­ey con­tract from BAR­DA for an­thrax

Josh Sullivan

Af­ter neg­a­tive feed­back from the FDA, the loss of busi­ness with As­traZeneca and the dis­rup­tion to the Covid-19 sup­ply chain, the US gov­ern­ment has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times